The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung cancer

The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung cancer

AMG-510 and cisplatin combination increases antitumor effect in lung adenocarcinoma with mutation of KRAS G12C: a preclinical and translational research

Frontiers Recent progress in targeted therapy for non-small cell lung cancer

The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung cancer

AMG-510 and cisplatin combination increases antitumor effect in lung adenocarcinoma with mutation of KRAS G12C: a preclinical and translational research

media.springer/m685/springer-static/imag

IJMS, Free Full-Text

Combinatorial tumor suppressor inactivation efficiently initiates lung adenocarcinoma with therapeutic vulnerabilities

Genotype-phenotype mapping of a patient-derived lung cancer organoid biobank identifies NKX2-1-defined Wnt dependency in lung adenocarcinoma - ScienceDirect